Interactions between Antidiabetic and Antiresorptive Medications on Glucose and Bone Metabolism:A System Review
Diabetes,a systemic metabolic disorder,poses intricate challenges in its treatment with the development of society and progress in medical treatment.Medications employed to manage diabetes not only target glucose levels but also elicit changes in bone metabolism.Some diabetes therapeutic agents,such as metformin and GLP-1 receptor agonists,exhibit a positive impact on bone health by elevating bone density and concurrently reducing the risk of fractures.In contrast,other medications like sulfonylureas,insulin,and thiazolidinediones may heighten the risk of bone fractures.Vigilance in selecting diabetes treatment drugs becomes crucial to prevent disruptions in bone metabolism.Monitoring and understanding the interplay between diabetes treatment drugs and bone health can aid in averting bone metabolic disorders.This proactive approach not only assists in managing osteoporosis in diabetic patients but also contributes to lowering the risk of fractures,ultimately enhancing their overall quality of life.Additionally,the realm of anti-osteoporosis medications,including bone resorption inhibitors and bone synthesis metabolism promoters,also exerts influence on the glucose metabolism of diabetes patients.For instance,bisphosphonates and denosumab,employed as bone resorption inhibi-tors,exhibit the potential to improve fasting blood sugar levels,thereby positively regulating glucose metabolism.Conversely,selective estrogen receptor modulators may decrease insulin sensitivity,adversely affecting glucose metabolism.In conclusion,a comprehensive review of the impact of diabetes drugs and anti-osteoporosis drugs on both bone and glucose metabolism reveals that metformin is beneficial for the bone metabolism of diabetic patients.Among the newer diabetes drugs,GLP-1 analogs play a positive role in bone metabolism,lowering the risk of fractures.For diabetic patients with existing osteoporosis,bisphosphonates stand out as recommended first-line drugs.In cases of impaired kidney function or severe osteoporosis,teriparatide emerges as a superior choice.This intricate relationship underscores the importance of a nuanced and personalized approach in managing both diabetes and bone health for opti-mal patient outcomes.
NETL
NSTL
万方数据
